Intravitreal low molecular weight heparin and 5-Fluorouracil for the prevention of proliferative vitreoretinopathy following retinal reattachment surgery

Cochrane Database of Systematic Reviews

Volumn 2013, Issue 1, 2013, Pages

  Sundaram, Venki ^a   Barsam, Allon ^b   Virgili, Gianni ^c  

^a LONDON SCHOOL OF HYGIENE AND TROPICAL MEDICINE   (United Kingdom)

^b MOORFIELDS EYE HOSPITAL   (United Kingdom)

^c UNIVERSITY OF FLORENCE   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

FLUOROURACIL; LOW MOLECULAR WEIGHT HEPARIN; PLACEBO;

ADJUVANT THERAPY; DRUG EFFICACY; EVIDENCE BASED MEDICINE; HIGH RISK PATIENT; HUMAN; MONOTHERAPY; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL (TOPIC); REOPERATION; RETINA DETACHMENT; RETINA SURGERY; RETINAL REATTACHMENT SURGERY; REVIEW; RISK REDUCTION; SCAR FORMATION; SURGICAL RISK; SYSTEMATIC REVIEW; TREATMENT RESPONSE; VISUAL ACUITY; VISUAL DISORDER; VITRECTOMY; VITREORETINOPATHY; INTRAVITREAL DRUG ADMINISTRATION; POSTOPERATIVE COMPLICATION;

FLUOROURACIL; HEPARIN, LOW-MOLECULAR-WEIGHT; HUMANS; INTRAVITREAL INJECTIONS; POSTOPERATIVE COMPLICATIONS; RANDOMIZED CONTROLLED TRIALS AS TOPIC; RETINAL DETACHMENT; VITREORETINOPATHY, PROLIFERATIVE;

MLCS; MLOWN;

EID: 84874792487     PISSN: None     EISSN: 1469493X     Source Type: Journal    
DOI: 10.1002/14651858.CD006421.pub3     Document Type: Review

References (31)

1. Asaria RH, Kon CH, Bunce C, Charteris DG, Wong D, Khaw PT, et al.Adjuvant 5-fluorouracil and heparin prevents proliferative vitreoretinopathy: results from a randomized, double-blind, controlled clinical trial. Ophthalmology 2001;108(7):1179-83.
2. Wickham L, Bunce C, Wong D, McGurn D, Charteris DG. Randomized controlled trial of combined 5-fluorouracil and low-molecular-weight heparin in the management of unselected rhegmatogenous retinal detachments undergoing primary vitrectomy. Ophthalmology 2007;114(4):698-704.
3. Scheer S, Morel C, Poisson F, Bonnel S, Touzeau O, Sahel JA, et al.Prevention of proliferative vitreoretinopathy using 5-FU heparin: clinical tolerance and efficacy. Journal Francais d' Opthalmologie 2005;28(7):701-6.
4. Wang Y, Wang LL, Zhu ZQ, Liu B, Pan AZ, Huang L. Electroretinogram of 5-fluorouracil and LMWH prevention of proliferative vitreoretinopathy. International Journal of Ophthalmology 2006;6(3):651-3.
5. Araiz JJ, Refojo MF, Arroyo MH, Leong FL, Albert DM, Tolentino FI. Antiproliferative effect of retinoic acid in intravitreous silicone oil in an animal model of proliferative vitreoretinopathy. Investigative Ophthalmology and Visual Science 1993;34(3):522-30.
6. Blumenkranz M, Hernandez E, Ophir A, Norton EW. 5-Fluorouracil: new applications in complicated retinal detachment for an established metabolite. Ophthalmology 1984;91(2):122-30.
7. Blumenkranz MS, Hartzer MK, Iverson D. An overview of potential applications of heparin in vitreoretinal surgery. Retina 1992;12(Suppl 3):S71-4.
8. Campochiaro PA, Hackett SF, Conway BP. Retinoic acid promotes density-dependent growth arrest in human retinal pigment epithelial cells. Investigative Ophthalmology and Visual Science 1991;32(1):65-72.
9. Daniels SA, Coonley KG, Yoshizumi MO. Taxol treatment of experimental proliferative vitreoretinopathy. Graefe's Archive for Clinical and Experimental Ophthalmology 1990;228(6):513-6.
10. Deeks JJ, Higgins JPT, Altman DG (editors). Chapter 9: Analysing data and undertaking meta-analyses. In: Higgins JPT, Green S (editors). Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 [updated March 2011]. The Cochrane Collaboration, 2011. Available from www.cochrane-handbook.org.
11. Fekrat S, de Juan E Jr, Campochiaro PA. The effect of oral 13-cis-retinoic acid on retinal redetachment after surgical repair in eyes with proliferative vitreoretinopathy. Ophthalmology 1995;102(3):412-8.
12. Glanville JM, Lefebvre C, Miles JN, Camosso-Stefinovic J. How to identify randomized controlled trials in MEDLINE: ten years on. Journal of the Medical Library Association 2006;94(2):130-6.
13. Heimann H, Zou X, Jandeck C, Kellner U, Bechrakis NE, Kreusel KM, et al.Primary vitrectomy for rhegmatogenous retinal detachment: an analysis of 512 cases. Graefe's Archive for Clinical and Experimental Ophthalmology 2006;244(1):69-78.
14. Higgins JPT, Altman DG (editors). Chapter 8: Assessing risk of bias in included studies. In: Higgins JPT, Green S (editors). Cochrane Handbook for Systematic Reviews of Interventions Version 5.0.2 [updated September 2009]. The Cochrane Collaboration, 2009. Available from www.cochrane-handbook.org.
15. Hui YN, Liang HC, Cai YS, Kirchhof B, Heimann K. Corticosteroids and daunomycin in the prevention of experimental proliferative vitreoretinopathy induced by macrophages. Graefe's Archive for Clinical and Experimental Ophthalmology 1993;231(2):109-14.
16. Iverson DA, Katsura H, Hartzer MK, Blumenkranz MS. Inhibition of intraocular fibrin formation following infusion of low-molecular-weight heparin during vitrectomy. Archives of Ophthalmology 1991;109(3):405-9.
17. Kirmani M, Santana M, Sorgente N, Wiedemann P, Ryan SJ. Antiproliferative drugs in the treatment of experimental proliferative vitreoretinopathy. Retina 1983;3(4):269-72.
18. Kumar A, Nainiwal S, Sreenivas B. Intravitreal low molecular weight heparin in PVR surgery. Indian Journal of Ophthalmology 2003;51(1):67-70.
19. Lean JS, Stern WH, Irvine AR, Azen SP. Classification of proliferative vitreoretinopathy used in the silicone study. The Silicone Study Group. Ophthalmology 1989;96(6):765-71.
20. Lemor M, Yeo JH, Glaser BM. Oral colchicine for the treatment of experimental traction retinal detachment. Archives of Ophthalmology 1986;104(8):1226-9.
21. Rachal WF, Burton TC. Changing concepts of failures after retinal detachment surgery. Archives of Ophthalmology 1979;97(3):480-3.
22. The Cochrane Collaboration. Review Manager (RevMan). 5.1. Copenhagen: The Nordic Cochrane Centre: The Cochrane Collaboration, 2011.
23. Anonymous. Vitrectomy with silicone oil or sulfur hexafluoride gas in eyes with severe proliferative vitreoretinopathy: results of a randomized clinical trial. Silicone Study Report 1. Archives of Ophthalmology 1992;110(6):770-9.
24. Tano Y, Sugita G, Abrams G, Machemer R. Inhibition of intraocular proliferations with intravitreal corticosteroids. American Journal of Ophthalmology 1980;89(1):131-6.
25. Tano Y, Chandler DB, McCuen BW, Machemer R. Glucocorticosteroid inhibition of intraocular proliferation after injury. American Journal of Ophthalmology 1981;91(2):184-9.
26. van Bockxmeer FM, Martin CE, Thompson DE, Constable IJ. Taxol for the treatment of proliferative vitreoretinopathy. Investigative Ophthalmology and Visual Science 1985;26(8):1140-7.
27. Verstraeten T, Hartzer M, Wilcox DK, Cheng M. Effects of vitamin A on retinal pigment epithelial cells in vitro. Investigative Ophthalmology and Visual Science 1992;33(10):2830-8.
28. White IR, Higgins JP, Wood AM. Allowing for uncertainty due to missing data in meta-analysis--part 1: two-stage methods. Statistics in Medicine 2008;27(5):711-27.
29. Wiedemann P, Lemmen K, Schmiedl R, Heimann K. Intraocular daunorubicin for the treatment and prophylaxis of traumatic proliferative vitreoretinopathy. American Journal of Ophthalmology 1987;104(1):10-4.
30. Wiedemann P, Leinung C, Hilgers RD, Heimann K. Daunomycin and silicone oil for the treatment of proliferative vitreoretinopathy. Graefe's Archive for Clinical and Experimental Ophthalmology 1991;229(2):150-2.
31. Sundaram V, Barsam A, Virgili G. Intravitreal low molecular weight heparin and 5-Fluorouracil for the prevention of proliferative vitreoretinopathy following retinal reattachment surgery. Cochrane Database of Systematic Reviews 2010, Issue 7. [DOI: 10.1002/14651858.CD006421.pub2]